New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Commentary|Articles|June 10, 2026
ASCO 2026 Ushers in a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Tracy Ann Politowicz
Oncology experts provide commentary on the meeting's biggest and most impactful presentations across the GI cancer continuum.
Advertisement
Advertisement
During the
Related to this article
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement